Actually the RBC analyst was correct or close to it! The $1 million revenue coming into SNY was stocking the drug with the retailers--CVS, Walgreen, etc. The analyst stated--'estimated prescriptions written' as being worth $250,000. If these numbers are anywhere near being correct, retailers inventory is still 75% of 1Q sales by SNY, and at this this rate of adoption there will be no need for retailers to stock any inventory for the 2nd Q. Meaning no revenue coming in for the next three months. I hope I'm wrong--but one shouldn't confuse inventory vs actual sales to end users. SNY makes money selling to retailers as they don't sell direct to patients. SNY has a lot of work cut out for them--going forward! I hope they make it!